Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05011383 · ClinicalTrials.gov registry record · Phase 2
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
A Phase 2 study of Metastatic Prostate Cancer, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 17
- Study locations
NCT05011383 is a Phase 2 study of Metastatic Prostate Cancer that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 51 participants, below the 185-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (72% lower). The trial reports 17 study locations across 13 states.
The verdict
NCT05011383, a Phase 2 study of Metastatic Prostate Cancer, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 17
- Study locations
Study Summary
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically unstable because of DNA repair deficiency and this is a prospective study to test that hypothesis
Conditions Studied
Interventions
- DRUG High dose testosterone
Study Locations (17)
Florida
- North Florida/South Georgia Veterans Health System, Gainesville, FL - Gainesville
- Orlando VA Medical Center, Orlando, FL - Orlando
Missouri
- Kansas City VA Medical Center, Kansas City, MO - Kansas City
- St. Louis VA Medical Center John Cochran Division, St. Louis, MO - St Louis
North Carolina
- Durham VA Medical Center, Durham, NC - Durham
- Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC - Salisbury
Tennessee
- Memphis VA Medical Center, Memphis, TN - Memphis
- Tennessee Valley Healthcare System Nashville Campus, Nashville, TN - Nashville
Colorado
- Rocky Mountain Regional VA Medical Center, Aurora, CO - Aurora
Connecticut
- VA Connecticut Healthcare System West Haven Campus, West Haven, CT - West Haven
Georgia
- Atlanta VA Medical and Rehab Center, Decatur, GA - Decatur
Kentucky
- Robley Rex VA Medical Center, Louisville, KY - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2021-08-31 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05011383
The ClinicalTrials.gov registry entry for NCT05011383 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 185-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (72% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which High dose testosterone is the first listed.
NCT05011383 reports 17 study locations spanning 13 distinct geographic areas - top geographies include Florida, Missouri, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05011383 about?
NCT05011383 is a clinical study titled "High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers". This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically uns...
What is the current status of trial NCT05011383?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2021-08-31. Estimated completion is 2027-08-31.
What conditions does trial NCT05011383 study?
This clinical trial studies the following conditions: Metastatic Prostate Cancer.
What interventions are being tested in trial NCT05011383?
The interventions under investigation include: High dose testosterone (DRUG).
Who is sponsoring clinical trial NCT05011383?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05011383 being conducted?
This trial has 17 study locations across Colorado, Connecticut, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
RECRUITING · Phase 2
-
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
RECRUITING · Phase 2
-
A Study of Tarlatamab for People With Prostate Cancer
RECRUITING · Phase 2
-
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
RECRUITING · Phase 2
-
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
RECRUITING · Phase 2
-
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.